Suppr超能文献

临床实践中心肌缺血及缺血后预处理:挑战、期望与障碍

Ischemic and postischemic conditioning of the myocardium in clinical practice: challenges, expectations and obstacles.

作者信息

Iliodromitis Efstathios K, Andreadou Ioanna, Iliodromitis Konstantinos, Dagres Nikolaos

机构信息

Second Department of Cardiology, Medical School, Attikon University Hospital, Athens, Greece.

出版信息

Cardiology. 2014;129(2):117-25. doi: 10.1159/000362499. Epub 2014 Sep 10.

Abstract

Conditioning refers to endogenous mechanisms rendering the myocardium more tolerant against reperfusion injury. Application of brief ischemia-reperfusion cycles prior to the index ischemia has a beneficial effect and limits the infarct size. This is called preconditioning and is mainly mediated by activation of adenosine, bradykinin, opioid and other receptors, with subsequent activation of intracellular mediators leading to mitochondrial protection. A clinical equivalent of preconditioning is preinfarction angina. Benefits for the ischemic and reperfused myocardium are also provided by repetitive short-lived cycles of ischemia-reperfusion applied after the index ischemia. This is termed postconditioning, shares a common pathway with preconditioning, and is more useful and relevant in clinical practice. Finally, benefits are also derived from remote conditioning, i.e. ischemia applied in a remote vascular territory parallel with or immediately after the index myocardial ischemia. Several pharmacological interventions may interfere with these mechanisms leading to enhanced protection of the myocardium and limitation of the infarct size. Despite the huge interest and the great body of evidence that verify the effectiveness of conditioning, clinical application has remained limited due to controversies over the appropriate intervention protocol, but also interference of medication, comorbidities and other factors that may enhance or blur the protective effect.

摘要

预处理是指使心肌对再灌注损伤更具耐受性的内源性机制。在初次缺血之前应用短暂的缺血-再灌注周期具有有益作用,并可限制梗死面积。这被称为预处理,主要由腺苷、缓激肽、阿片类和其他受体的激活介导,随后细胞内介质的激活导致线粒体保护。预处理的临床等效情况是梗死前心绞痛。初次缺血后应用重复性短暂缺血-再灌注周期也可为缺血和再灌注心肌带来益处。这被称为后处理,与预处理有共同途径,且在临床实践中更有用且相关。最后,益处也来自远隔预处理,即在初次心肌缺血同时或之后在远隔血管区域施加缺血。几种药理学干预可能会干扰这些机制,从而增强对心肌的保护并限制梗死面积。尽管对预处理的有效性有极大兴趣且有大量证据证实,但由于对适当干预方案存在争议以及药物、合并症和其他可能增强或模糊保护作用的因素的干扰,其临床应用仍然有限。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验